Atomoxetine, Placebo and Parent Management Training in Autism

Overview

The study will evaluate the effectiveness of atomoxetine (Strattera) with and without Parent Management Training (PMT) in children with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDDNOS) who have symptoms of Attention Deficit Hyperactivity Disorder (ADHD). This is a double-blind placebo, parallel study where the atomoxetine will have a dose titration over a 6 week period. All children will be seen weekly during this titration period, with additional visits at Week 8 and Week 10. Families assigned to the PMT arm will have an additional weekly meeting with a clinician for a total of 9 PMT visits. PMT involves teaching parents to implement behavioral interventions with their children. Subjects who are clinical responders (ADHD Responders and Compliance Responders) from the 10 week study period will be followed every 4 weeks in a 24-week extension study. Subjects who are clinical nonresponders will continue in PMT if they received PMT during the double-blind phase, and they will receive an open trial of atomoxetine if they were on placebo during the double-blind phase. All subjects (responders and nonresponders) will be invited to participate in follow-up assessments every 4 weeks for 24 weeks after the completion of the double-blind phase.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: April 2014

Interventions

  • Drug: atomoxetine
    • atomoxetine
  • Drug: Placebo
    • Placebo + parent management treatment
  • Behavioral: Parent Management Training

Arms, Groups and Cohorts

  • Active Comparator: 1
    • Atomoxetine + Parent Management Training
  • Active Comparator: 2
    • Atomoxetine without Parent Management Training
  • Placebo Comparator: 3
    • Placebo + Parent Management Training
  • Placebo Comparator: 4
    • Placebo without Parent Management Training

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents
    • Time Frame: week 10
    • Respondents were defined as having ≥30% decrease on the SNAP and CGI-I<=2). The Swanson, Nolan, and Pelham (SNAP)-IV Parent and Teacher Rating Scales were used to measure ADHD and oppositional symptoms at home and school. The SNAP-IV ADHD section contains items for each of the 18 Diagnostic and Statistical Manual of Mental Disorders-IV symptoms of ADHD rated from 0 (not at all) to 3 (very much). The Clinical Global Impressions Scale (CGI) includes subscales for severity of illness and global improvement. The Severity scale is scored from 1 (normal) to 7 (extremely ill), with a rating of ≥4 required for inclusion. The Improvement score ranged from 1 (very much improved) through 4 (no change) to 7 (very much worse). The CGI was completed by a blinded rater based on parent/child interview and review of completed parent and school behavior problem questionnaires at each study visit.
  • Percentage of Participants Who Were Autism Spectrum Disorder Respondents
    • Time Frame: week 10
    • Respondents were defined as having ≥30% decrease on the HSQ and CGI-I≤2). The 25-item HSQ was adapted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate behavioral noncompliance in children with autism spectrum disorder (ASD). The Home Situations Questionnaire – Pervasive Developmental Disorder (HSQ) is a 25-item parent rating scale assessing noncompliance. Parents are asked to indicate whether each item is a problem and, if so, its severity from 1 (mild) to 9 (severe). The School Situations Questionnaire (SSQ) is a 9-item teacher rating scale that assesses noncompliance. The SSQ is a companion instrument to the HSQ and uses the same rating scale. The Clinical Global Impressions Scale (CGI) includes subscales for severity of illness and global improvement. The Severity scale is scored from 1 (normal) to 7 (extremely ill),

Participating in This Clinical Trial

Inclusion Criteria

  • Children 5 yrs to 14 years 11 mos with clinical diagnosis of Autism, Asperger's Disorder, or PDDNOS based upon the ADI-R and clinical evaluation by DSM-IV criteria, – Mental age equal to or greater than 24 months, – ADHD symptoms based upon the CASI and clinical confirmed diagnosis, – CGIS-S rating of 4 or grater for ADHD symptoms, – A mean item score of >1.5 on both the Parent and Teacher (non-parent caregiver) SNAP-IV 18 ADHD symptoms or the 9-symptom hyperactive-impulsive subscale (symptoms must be cross-situational), – Reliable care provider available to bring subject to clinic visits and weekly sessions. Exclusion Criteria:

  • DSM-IV diagnosis of schizophrenia, schizoaffective disorder psychotic disorder NOS,bipolar disorder, or major depression (if accompanied by a family history of bipolar disorder) based upon evidence of suicidality, CASI, and clinical interview/history, – Prior failed adequate trial of atomoxetine, – Use of other psychotropic medications that produce CNS effects, – Diagnosis of bipolar disorder, major depression, hypertension, cardiovascular disease, narrow angle glaucoma, other significant physical illness, – Pregnancy or sexually active females (intercourse in the past 6 months, reported by either the subject or caregiver), – Currently on effective medication treatment for ADHD, – Prior involvement in Parent Management Training or other similar program, – Currently on albuterol or taking beta blockers, – Taking supplements or other complementary medical treatments where dose cannot be held at current level for duration of study

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: 14 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Rochester
  • Collaborator
    • University of Pittsburgh
  • Provider of Information About this Clinical Study
    • Principal Investigator: tristram smith, Associate Professor – University of Rochester
  • Overall Official(s)
    • Benjamin Handen, PhD, Principal Investigator, University of Pittsburgh Medical Center
    • Michael Aman, PhD, Principal Investigator, Ohio State University
    • Tristram Smith, PhD, Principal Investigator, University of Rochester

Citations Reporting on Results

Chowdhury M, Aman MG, Scahill L, Swiezy N, Arnold LE, Lecavalier L, Johnson C, Handen B, Stigler K, Bearss K, Sukhodolsky D, McDougle CJ. The Home Situations Questionnaire-PDD version: factor structure and psychometric properties. J Intellect Disabil Res. 2010 Mar;54(3):281-91. doi: 10.1111/j.1365-2788.2010.01259.x.

Barkley, R. A., & Edelbrock, C. (1987). Assessing situational variation in children's problem behaviors: The Home and School Situations Questionnaires. In R. Prinz (Ed.), Advances in behavioral assessment of children and families (pp. 157-176). Greenwich, CT: JAI Press Inc

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.